11 小时
AZoLifeSciences on MSNTargeting NMDA Receptor Subunit Shows Promise for Fragile X SyndromeBuilding on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...
MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...
MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.
Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...
Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to ...
Mizuho lowered the firm’s price target on Harmony Biosciences (HRMY) to $42 from $52 and keeps an Outperform rating on the shares. The firm ...
According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...
A growth occurring in the next five years will be fuelled by the launch of two high-priced pipeline products providing ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果